Neuronetics Enhances Workforce with New Stock Awards
In an exciting development, Neuronetics, Inc. (NASDAQ: STIM), a pioneering medical technology company, has recently announced the granting of inducement awards in the form of Restricted Stock Units (RSUs) for a total of 13,500 shares. This initiative marks a significant step as part of their strategy to attract talent and strengthen their team. The awards were formally approved by the Compensation Committee of Neuronetics, aligning with Nasdaq's Listing Rule 5635(c)(4). This strategic move is designed to entice seven new non-executive employees to join the ranks of Neuronetics and contribute to its innovative endeavors.
Understanding the Grant Structure
Each stock unit comes with a vesting schedule that offers equal installments over three years, specifically on the first, second, and third anniversaries of the grant date. This structure not only incentivizes the employees but also encourages them to remain committed to the company throughout the vesting period. Such carefully constructed plans are crucial in today’s competitive job market, as they reflect Neuronetics’ intention to cultivate a dedicated and well-supported workforce.
About Neuronetics: A Leader in Neurohealth
Neuronetics believes in the importance of mental health, matching it on par with physical health. As a global leader in the field of neuroscience, it stands as the largest company in the transcranial magnetic stimulation (TMS) industry. The company has worked tirelessly to redefine patient and physician expectations, focusing on product designs that aim to significantly elevate the quality of life for those battling neurohealth disorders.
A Revolutionary Treatment Option
One of the hallmark offerings of Neuronetics is the NeuroStar® Advanced Therapy system, an FDA-cleared, non-invasive treatment designed to assist individuals grappling with depression. To date, over 6.9 million treatments have been administered, highlighting the system's credibility and effectiveness. Built on the foundation of extensive clinical research, NeuroStar holds the largest dataset for TMS treatment outcomes, proving its efficacy and reliability.
Expanding Treatment Horizons
Beyond addressing major depressive disorders, the NeuroStar Advanced Therapy system is also FDA-cleared for the treatment of obsessive-compulsive disorder and for alleviating comorbid anxiety symptoms in adults suffering from major depressive disorder. This expansion of treatment capabilities not only showcases Neuronetics’ commitment to inclusive healthcare solutions but also stands to significantly improve the patient experience across a spectrum of mental health challenges.
Commitment to Innovation and Patient Care
With its relentless dedication to improving lives, Neuronetics aims to provide groundbreaking treatment options that generate remarkable outcomes. The emphasis on continuous innovation sets Neuronetics apart as a vanguard in the mental health landscape.
Investor and Media Relations
For those interested in further information, Neuronetics encourages inquiries from investors and media contacts. Investors can reach out to Mike Vallie or Mark Klausner at ICR Westwicke by calling 443-213-0499 or via email at ir@neuronetics.com for investor relations. For media inquiries, the EvolveMKD team can be contacted at 646-517-4220 or via email at NeuroStar@evolvemkd.com.
Frequently Asked Questions
What are the recent inducement awards at Neuronetics?
Neuronetics has issued inducement awards of 13,500 RSUs to attract new non-executive employees, enhancing their team’s capabilities.
How does the RSU vesting schedule work?
The RSUs vest in equal installments over three years, contingent upon the employee's continued service at Neuronetics.
What is the mission of Neuronetics?
Neuronetics is committed to improving the quality of life for patients suffering from neurohealth disorders through innovative medical technologies.
What treatments does the NeuroStar system provide?
The NeuroStar system is FDA-cleared for treating major depressive disorder, obsessive-compulsive disorder, and anxiety symptoms related to depression.
How can I contact Neuronetics for investor relations?
Investors can contact Mike Vallie or Mark Klausner at ICR Westwicke by calling 443-213-0499 or emailing ir@neuronetics.com.
